Zhang Yujie, Yu Chaoran
Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.
Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200025, P.R. China.
Oncol Lett. 2020 Mar;19(3):1831-1841. doi: 10.3892/ol.2020.11253. Epub 2020 Jan 7.
The replication protein A (RPA)1-4 family are single-stranded DNA-binding proteins that are essential components of DNA replication, repair and recombination, and cell cycle regulation. The present study aimed to evaluate the prognostic value of the RPA family members in patients with gastric cancer (GC), using datasets retrieved from the Oncomine public database. Datasets were retrieved for the purpose of comparing the RPA expression levels between GC and normal tissues. Additionally, Kaplan-Meier analysis was used to compare the overall survival (OS) times of GC patients that expressed different levels of RPA proteins. RPA1, 2, and 3 expression levels were all significantly upregulated in gastric intestinal-type, diffuse gastric, and gastric mixed adenocarcinomas, compared with those in normal mucosal tissues. Moreover, high mRNA expression levels of RPA3 and 4 predicted poorer OS times in all GCs, as well as patients with human epidermal growth factor receptor 2-negative and -positive GC. The high-risk group, separated by RPA signature, showed a poorer outcome than the low-risk group. RPA3 was the most strongly correlated with CD4+ T-cell levels. In conclusion, RPAs are novel prognostic indicators in GC, and can also predict the features of immunological diseases. Future experimental investigation into the roles of RPAs concerning the pathogenesis and development of GC may provide a novel biomarker or therapeutic target, improving the prognosis of patients with GC.
复制蛋白A（RPA）1 - 4家族是单链DNA结合蛋白，是DNA复制、修复和重组以及细胞周期调控的重要组成部分。本研究旨在利用从Oncomine公共数据库检索到的数据集，评估RPA家族成员在胃癌（GC）患者中的预后价值。检索数据集以比较GC组织和正常组织之间的RPA表达水平。此外，采用Kaplan - Meier分析比较表达不同水平RPA蛋白的GC患者的总生存期（OS）。与正常黏膜组织相比，RPA1、2和3在胃肠型、弥漫性胃癌和胃混合腺癌中的表达水平均显著上调。此外，RPA3和4的高mRNA表达水平预示着所有GC患者以及人表皮生长因子受体2阴性和阳性GC患者的OS时间较差。根据RPA特征分离出的高危组比低危组预后更差。RPA3与CD4 + T细胞水平相关性最强。总之，RPA是GC的新型预后指标，还可预测免疫疾病特征。未来关于RPA在GC发病机制和发展中作用的实验研究可能会提供一种新型生物标志物或治疗靶点，改善GC患者的预后。
